15-Year watch begins for new cancer cell therapy
NCT ID NCT06985576
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 18 people who previously received GF-CART01, a CAR T-cell therapy for certain blood cancers like lymphoma. Researchers will track side effects and how long the modified cells last in the body for up to 15 years. The goal is to ensure the treatment remains safe over the long term.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GF-CART01 (a type of CAR T-cell therapy targeting CD20 and CD19 proteins on cancer cells)
- What this could lead to
- If successful, this study will confirm the long-term safety and durability of GF-CART01, supporting its use as a treatment for certain blood cancers.
- What could go wrong
- This is a small, observational follow-up study with only 18 participants, so results may not apply to everyone. It does not test new treatments, only monitors past ones.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Four-Pronged attack beat brain lymphoma?
- What happens years after CAR-T therapy? a study aims to find out
- Can a new drug combo outsmart resistant lymphomas?